Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2009

Open Access 01-12-2009 | Review

Antiphospholipid antibodies: Paradigm in transition

Authors: Lawrence L Horstman, Wenche Jy, Carlos J Bidot, Yeon S Ahn, Roger E Kelley, Robert Zivadinov, Amir H Maghzi, Masoud Etemadifar, Seyed Ali Mousavi, Alireza Minagar

Published in: Journal of Neuroinflammation | Issue 1/2009

Login to get access

Abstract

Objectives

This is a critical review of anti-phospholipid antibodies (aPL). Most prior reviews focus on the aPL syndrome (APS), a thrombotic condition often marked by neurological disturbance. We bring to attention recent evidence that aPL may be equally relevant to non-thrombotic autoimmune conditions, notably, multiple sclerosis and ITP.

Organization

After a brief history, the recent proliferation of aPL target antigens is reviewed. The implication is that many more exist. Theories of aPL in thrombosis are then reviewed, concluding that all have merit but that aPL may have more diverse pathological consequences than now recognized. Next, conflicting results are explained by methodological differences. The lupus anticoagulant (LA) is then discussed. LA is the best predictor of thrombosis, but why this is true is not settled. Finally, aPL in non-thrombotic disorders is reviewed.

Conclusion

The current paradigm of aPL holds that they are important in thrombosis, but they may have much wider clinical significance, possibly of special interest in neurology.
Literature
1.
Eng A: Cutaneous expression of antiphospholipid syndromes. Sem Thomb Haemost. 1994, 20: 71-78. 10.1055/s-2007-1001891.
2.
Conley CL, Hartman RC: A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952, 31: 621-622.
3.
Harris EN, Charavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV: Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983, 2: 1211-1214. 10.1016/S0140-6736(83)91267-9.PubMed
4.
Harris EN, Charavi AE, Hedge U, Derue G, Morgan SH, Englert H, Chan JKH, Asherson RA, Hughes GRV: Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Brit J Haematol. 1985, 59: 231-234. 10.1111/j.1365-2141.1985.tb02989.x.
5.
Hughes GRV, Harris EN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol. 1985, 13: 486-489.
6.
Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J: Antiphospholipid antibodies and venous thromboembolism. Blood. 1995, 86: 3685-3691.PubMed
7.
Triplett DR: Protean clinical presentations of antiphospholipid antibodies (APA). Thromb Haemost. 1995, 74: 329-337.PubMed
8.
Galli M, Barbui T: Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood. 1999, 93: 2149-2157.PubMed
9.
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999, 42: 1309-1311. 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F.PubMed
10.
Lockshin MD, Sammaritano LR, Schwartzman S: Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 2000, 43: 440-443. 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N.PubMed
11.
Arnout J: Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost. 2001, 86: 83-91.PubMed
12.
Rand JH, Macik BG, Konkle BA: Thrombophilia: What's a practitioner to do? (Diagnosis and treatment of the antiphospholipid syndrome). Edited by: Schecter GP, Broudy VC, Williams ME, Bajus JL. 2001, American Society of Hematology Education Program Book. Chapel Hill, NC, 322-324.
13.
Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome (Review). N Engl J Med. 2002, 346: 752-763. 10.1056/NEJMra002974.PubMed
14.
Brey RL, Levine SR, Stallworth CL: Neurologic manifestations in the antiphospholipid syndrome. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Edited by: Asherson RA, Cervera R, Piette JC, Shoenfeld Y. 2002, New York: Elsevier, 155-168.
15.
Hughes GRV: The antiphospholipid syndrome: ten years on. Lancet. 1993, 342: 341-344. 10.1016/0140-6736(93)91477-4.PubMed
16.
Roubey RAS: Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996, 39: 1444-1454. 10.1002/art.1780390903.PubMed
17.
Vermylen J, Hoylaerts MF, Arnout J: Antibody-mediated thrombosis. Thromb Haemost. 1997, 78: 420-426.PubMed
18.
Galli M, Finazzi G, Barbui T: Antiphospholipid antibodies: predictive value of laboratory tests. Thromb Haemost. 1997, 78: 75-78.PubMed
19.
Esmon NL, Smirnov MD, Esmon CT: Thrombogenic mechanisms of antiphospholipid antibodies (State of the Art). Thromb Haemost. 1997, 78: 79-82.PubMed
20.
Greaves M: Antiphospholipid antibodies and thrombosis [for comments, see v354:71-3]. Lancet. 1999, 353: 1348-1353. 10.1016/S0140-6736(98)10362-8.PubMed
21.
Arnout J, Vermylen J: Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost. 2003, 1: 931-942. 10.1046/j.1538-7836.2003.00125.x.PubMed
22.
Giannakopoulos B, Passam F, Rahgozar S, Krilis SA: Curent concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007, 109: 422-430. 10.1182/blood-2006-04-001206.PubMed
23.
Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T: Anticardiolipin cofactor(s) and differential diagnosis of autoimmune diseases. Lancet. 1990, 336: 177-178. 10.1016/0140-6736(90)91697-9.PubMed
24.
Galli M, Comfurius P, Maassen C, Hemker HC, DeBaets MH, vanBreda-Vriesman TJC, Barbui T, Zwaal RFA, Bevers EM: Anticardiolipin antibodies directed not to cardiolipin but to a plasma cofactor. Lancet. 1990, 335: 1544-1547. 10.1016/0140-6736(90)91374-J.PubMed
25.
McNeil HP, Simpson RJ, Chesterman CN, Krillis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2 glycoprotein 1 (apolipoprotein H). Proc Nat Acad Sci USA. 1990, 87: 4120-4124. 10.1073/pnas.87.11.4120.PubMedCentralPubMed
26.
Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GRV: β2-glycoprotein 1 reactivity of monoclonal antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 1994, 37: 1453-1461. 10.1002/art.1780371008.PubMed
27.
Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO: Reactivity to beta 2 glycoprotein 1 clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost. 1996, 75: 717-720.PubMed
28.
Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J: Beta-2-glycoprotein 1 dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein 1 complexes on phospholipid surfaces. Thromb Haemost. 1998, 79: 79-86.PubMed
29.
Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC: Autoantibodies to β2-glycoprotein 1 in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol. 1999, 25: 667-674.
30.
Arvieux J, Roussel B, Jacob MC, Colomb MG: Measurement of anti-phospholipid antibodies by ELISA using β2-glycoprotein 1 as an antigen. J Immunol Meth. 1991, 143: 223-229. 10.1016/0022-1759(91)90047-J.
31.
McIntyre JA, Wagenknecht DR, Sugi T: Phospholipid binding plasma proteins required for antiphospholipid antibody detection: an overview. Am J Reprod Immunol. 1997, 37: 101-110.PubMed
32.
Roubey RA: Autoantibodies to phospholipid binding proteins: a new view of lupus anticoagulants and other 'antiphospholipid' autoantibodies. Blood. 1994, 84: 2854-2867.PubMed
33.
Schultz DR: Antiphospholipid antibodies: basic immunology and assays. Sem Arthritis Rheum. 1997, 26: 724-739. 10.1016/S0049-0172(97)80041-8.
34.
Petrovas C, Vlachoyoannopoulos PG, Kordossis T, Moutsopoulos HM: Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GP1. J Autoimm. 1999, 13: 347-355. 10.1006/jaut.1999.0324.
35.
Loizou S, Singh S, Wypkema E, Asherson RA: Anticardiolipin, anti-beta2-glycoprotein 1 and antiprothrombin antibodies in black South African patients with infectious diseases. Ann Rheum Dis. 2003, 62: 1106-1111. 10.1136/ard.62.11.1106.PubMedCentralPubMed
36.
Chairman , Arnout J: ISTH Scientific Standardization Subcommittee: Lupus Anticoagulants/Phospholipid-Dependent Antibodies. Boston, MA. 2002, International Society of Thrombosis and Haemostasis (ISTH)
37.
Nash MJ, Camiller RS, Kunka S, Mackie IJ, Machin SJ, Cohen H: The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost. 2004, 2: 1077-1081. 10.1111/j.1538-7836.2004.00810.x.PubMed
38.
Meroni PL, Tincani A: Should our approach to the anticardiolipin assay change 20 years after its discovery? [Commentary on Nash, et al, pg 1077]. J Thromb Haemost. 2004, 2: 1074-1076. 10.1111/j.1538-7836.2004.00817.x.PubMed
39.
DeMoerloose P, Reber G: Antiphospholipid antibodies: do we still need to perform anticardiolipin ELISA assays? [Commentary on Nash, et al, pg 1077]. J Thromb Haemost. 2004, 2: 1071-1073. 10.1111/j.1538-7836.2004.00811.x.
40.
Harris NE, Goldsmith G, Pierangeli S, Gharavi A, Branch W: Phospholipid binding antibodies warrant continued investigation. Blood. 1995, 85: 2276-2285.PubMed
41.
Pierangeli SS, Harris EN, Gharavi AE, Goldsmith G, Branch DW, Dean WL: Are immunoglobulins with lupus anticoagulant activity specific for phospholipids?. Br J Haematol. 1993, 85: 124-132. 10.1111/j.1365-2141.1993.tb08655.x.PubMed
42.
McIntyre JA, Wagenknecht DR, Faulk WP: Antiphospholipid antibodies: discovery, definitions, detection and disease. Prog Lipid Res. 2003, 42: 176-237. 10.1016/S0163-7827(02)00048-6.PubMed
43.
Merrill JT: Which antiphospholipid antibody tests are most useful?. Rheum Dis Clin North Am. 2001, 27: 525-549. 10.1016/S0889-857X(05)70218-0.PubMed
44.
vonLandenberg C, Lackner KJ, vonLandenberg P, Lang B, Schmitz G: Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimm. 1999, 13: 215-223. 10.1006/jaut.1999.0316.
45.
Sorice M, Circella A, Griggi T, Garofalo T, Nicodemo G, Pittoni V, Ponteri GM, Lenti L, Valewsini G: Anticardiolipin and anti-β2-GP-I are two distinct populations of autoantibodies. Thromb Haemost. 1996, 75: 303-308.PubMed
46.
Haynes BF, Fleming J, StClair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM: Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005, 308: 1906-1908. 10.1126/science.1111781.PubMed
47.
Metzger J, vonAndenbeerg P, Keerel M, Buhl A, Lackner KL, Luppa PB: Biosensor analysis of beta-2-glycoprotein I reactive autoantibodies: Evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies. Clin Chem. 2007, 53: 1137-1143. 10.1373/clinchem.2006.079632.PubMed
48.
Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV: Specificity of ELISA for antibody to β2-glycoprotein 1 in patients with antiphospholipid syndrome. Br J Rheumatol. 1996, 35: 1239-1243. 10.1093/rheumatology/35.12.1239.PubMed
49.
Amiral J, Larrivaz I, Cluzeau D, Adam M: Standardization of immunoassays for antiphospholipid antibodies with β2 GP1 and role of other phospholipid cofactors. Haemostasis. 1994, 24: 191-203.PubMed
50.
Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RFA: Effects of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol. 1993, 83: 466-472. 10.1111/j.1365-2141.1993.tb04672.x.PubMed
51.
Sugi T, McIntyre JA: Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by anti-phosphatidylethanolamine antibodies. Thromb Haemost. 1996, 76: 354-360.PubMed
52.
Sugi T, McIntyre JA: Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimm. 2001, 17: 207-214. 10.1006/jaut.2001.0543.
53.
Tomas JF, Tomas JF, Alberca I, Tabernero MD, Cordero M, DelPino-Montes J, Vicente V: Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol. 1998, 25: 57-61.PubMed
54.
Pratico D, Ferro D, Iuliano L, Rokach J, Conti F, Valesini G, FitzGerald GA, Violi F: Ongoing prothrombotic state in patients with antiphospholipid antibodies: A role for increased lipid peroxidation. Blood. 1999, 93: 3401-3407.PubMed
55.
Pratico D, Tangirala RK, Horkko S, Witztum JL, Palinski W, FitzGerald GA: Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F2 alpha-VI levels and the extend of atherosclerosis in ApoE-deficient mice: modulation by vitamin E. Blood. 2001, 97: 459-464. 10.1182/blood.V97.2.459.PubMed
56.
Horkko S: The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci USA. 1997, 94: 10356-10361. 10.1073/pnas.94.19.10356.PubMedCentralPubMed
57.
Lopes-Virella MF, Virela G, rchard TJ, Koshkinen S, Evans RW, Becker DJ, Forrest KYZ: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999, 90: 165-172. 10.1006/clim.1998.4631.PubMed
58.
Ames PRJ, Nourooz-Zadeh JN, Tommasino C, Alvez J, Brancaccio C, Anggard EE: Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost. 1998, 79: 447-449.PubMed
59.
Amengual O, Atsumi T, Kamashta MA, Hughes GRV: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost. 1998, 79: 276-281.PubMed
60.
Cugno M, Dominguez M, Cabibbe M, Bisiani G, Galli M, Angles-Cano E, Agostoni A: Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol. 2000, 108: 871-875. 10.1046/j.1365-2141.2000.01948.x.PubMed
61.
Hurtado V, Montes R, Gris JC, Bertolaccini ML, Alonso A, Martinez-Gonzalez MA, Khamashta MA, Fukudome F, Lane DA, Hermida J: Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood. 2004, 104: 1369-1374. 10.1182/blood-2004-03-0793.PubMed
62.
vanHylckama VA, Montes R, Rosendaal FR, Hermida J: Autoantibodies against endothelial protein C receptor and the risk of a first deep vein thrombosis. J Thromb Haemost. 2007, 5: 1449-1454. 10.1111/j.1538-7836.2007.02582.x.
63.
Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JMR, Lollar P: Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood. 2001, 97: 169-174. 10.1182/blood.V97.1.169.PubMed
64.
Asada Y, Sumiyoshi A, Hayashi T, Syzymiya J, Kaketani K: Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985, 38: 469-479. 10.1016/0049-3848(85)90180-X.PubMed
65.
Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D: The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood. 1997, 89: 3663-3671.PubMed
66.
Lollar P: Pathogenic antibodies to coagulation factors. Part I. Factor VIII and IX. J Thromb Haemost. 2004, 2: 1082-1095. 10.1111/j.1538-7836.2004.00802.x.PubMed
67.
Lollar P: Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor. J Thromb Haemost. 2005, 3: 1385-1391. 10.1111/j.1538-7836.2005.01228.x.PubMed
68.
Jones DW, Gallimore MJ, Harris SL, Winter M: Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost. 1999, 81: 387-390.PubMed
69.
Galli M, Luciani D, Bertolini G, Barbui T: Anti-beta-2-glycoprotein 1, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003, 102: 2717-2713. 10.1182/blood-2002-11-3334.PubMed
70.
Galli M: Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Sem Thromb Hemost. 2008, 34: 329-334. 10.1055/s-0028-1085474.
71.
Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, DeStefanon V, Berrettini M, Barbui T: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med. 1996, 100: 530-536. 10.1016/S0002-9343(96)00060-5.PubMed
72.
Muriel M, Sarzi-Puttini P, Peretti R, Rossi E, Atzeni F, Parsons W, Doria A: Thrombotic risk factors in primary antiphospholipid syndrome: A 5-year prospective study. Stroke. 2005, 36: 1490-1494. 10.1161/01.STR.0000170645.40562.09.
73.
Lien LM, Chen WH, Chiu HC, Pan WH, Chen JR, Bai CH: High titers of anticardiolipin antibody is associated with first-ever ischemic stroke in Taiwan. Cerebrovasc Dis. 2006, 22: 225-230. 10.1159/000094008.PubMed
74.
McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortell TL, Triplett DA, Victoria EJ, Linnik MD: β2 glycoprotein I-dependant anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein 1. Thromb Haemost. 2001, 86: 590-595.PubMed
75.
Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y, Kawakami Y: Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells [with editorial by Vickers and Greaves, p1371]. Blood. 2005, 105: 1552-1557. 10.1182/blood-2004-08-3145.PubMed
76.
deLaat B, Derksen RHWM, Urbanus RT, deGroot PG: IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoptorein I cause LAC, and their presence correlates strongly with thrombosis [With editorial by Vickers and Greaves, pg 1371]. Blood. 2005, 105: 1540-1545. 10.1182/blood-2004-09-3387.
77.
Yasuda S, Atsumi T, Ieko M, Kobayashi K, Inagaki J, Kato H, Tanaka H, Yamakada M, Akino M, Saitou M, Aamasaki Y, Jodo S, Amengual O, Koike T: Nicked beta-2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood. 2004, 103: 3766-3772. 10.1182/blood-2003-08-2712.PubMed
78.
Hulstein JJJ, Lenting PJ, deLaat B, Derksen RHWM, Fijnheer R, deGroot PG: Beta-2-glycoprotein I inhibits von Willebrand factor-dependant platelet adhesion and aggregation. Blood. 2007, 110: 1483-1491. 10.1182/blood-2006-10-053199.PubMed
79.
Carron JA, Bates RC, Smith AI, Tetoz T, Arellano A, Gordon DL, Burns GF: Factor H co-purifies with thrombospondin isolated from platelet concentrates. Biochem Biophys Acta, Gene Struct Exp. 1996, 1289: 305-311. 10.1016/0304-4165(95)00095-X.
80.
Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RF: Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim Biophys Acta. 1986, 884: 142-149.PubMed
81.
Nimpf J, Wurm H, Kostner GM: β2-glyoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atheroscler. 1987, 63: 109-114. 10.1016/0021-9150(87)90110-9.
82.
Schousboe I: β2-glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood. 1985, 66: 1086-1091.PubMed
83.
McNally T, Mackie IJ, Isenberg DA, Machin SJ: β2 glycoprotein-1 inhibits factor XII activation on triglyceride rich lipoproteins: The effect of antibodies from plasma of patients with antiphospholipid syndrome. Thromb Haemost. 1996, 76: 220-225.PubMed
84.
Pengo V, Biasiolo A, Brocco T, Rampazzo P: Effect of anti-β2 glycoprotein I lupus anticoagulants on fibrin polymerization and fibrinolysis. Autoimmunity. 2000, 332: 39-44.
85.
Arvieux J, Regnault V, Hachulla E, Darnige L, Berthou F, Youinou P: Oxidation of β2-glycoprotein 1 (β2GPI) by the hydroxyl radical alters phospholipid binding and modulators recognition by anti-β2GPI autoantibodies. Thromb Haemost. 2001, 86: 1070-1076.PubMed
86.
Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K: β2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost. 1996, 75: 49-55. 10.1159/000134456.PubMed
87.
Dunoyer-Geindre S, Kruithof EKO, Galve-deRochemonteix B, Rosnblet C, Gruenberg J, Reber G, deMoerloose P: Localization of β2-glycoprotein 1 in late endosomes of human endothelial cells. Thromb Haemost. 2001, 85: 903-907.PubMed
88.
Esmon CT: The endothelial protein C receptor. Thromb Haemost. 2000, 83: 639.PubMed
89.
Dahlback B, Villoutreix BO: Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost. 2003, 1: 1525-1534. 10.1046/j.1538-7836.2003.00299.x.PubMed
90.
Anderson BD, Bisgaard ML, Lind B, Philips M, Villoutreix BO, Thorsen S: Characterization and structural impact of five novel PROS1 mutations in eleven protein S deficient families. Thromb Haemost. 2001, 86: 1392-1399.
91.
Rezende SM, Simmonds RE, Lane DA: Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-CDb-binding protein complex. Blood. 2004, 104: 1192-1201.
92.
Takahashi H, Tatewaki W, Nakamura T, Hanano M, Wada K, Shibata A: Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S. Am J Hematol. 1989, 30: 14-21. 10.1002/ajh.2830300104.PubMed
93.
Oosting J, Derkson RHWM, Bobbink IWG, Hackeng TM, Bouma BN, deGroot PG: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanisms?. Blood. 1993, 81: 2618-2625.PubMed
94.
Merrill JT, Zhang HW, Shen C, Butman BT, Jeffries EP, Lahita RG, Myones BL: Enhancement of protein S anticoagulant function by β2-glycoprotein 1, a major target antigen of antiphospholipid antibodies: β2-clycoprotein 1 interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost. 1999, 81: 748-757.PubMed
95.
Bick RL, Pegram M: Syndromes of hypercoagulability and thrombosis: a review. Sem Thomb Haemost. 1994, 20: 109-128. 10.1055/s-2007-1001895.
96.
Duchemin J, Baden-Meunier B, Proulle V, Nouyrigat V, Goujard C, Grimaux M, Devictor D, Tchernia M, Dreyfus M: Lupus anticoagulant occurring during so-called "benign" infectious diseases may be associated with auto-immune transient protein S deficiency and thrombosis. Thromb Haemost. 2001, Supl (July): Ab #P2069.
97.
Nojima J, Kuratsu H, Suehisa E, Futsukaichi Y, Yamanishi J, Machii T, Iwatani Y, Kanakura Y: Association between the prevalence of antibodies to β2-glycoprotein 1, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications [with editorial, p985]. Clin Chem. 2001, 47: 1008-1015.PubMed
98.
Galli M: Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?. J Autoimm. 2000, 15: 101-105. 10.1006/jaut.2000.0413.
99.
Swadzba J, DeClerck LS, Stevens WJ, Bridts CH, vanCotthem KA, Musial J: Anticardiolipin, anti-beta2-glycoprotein 1, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol. 1997, 24: 1710-1715.PubMed
100.
Pengo V, Basiolo A, Brocco T, Torietto S, Ruffati A: Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid reactive antibodies. Thromb Haemost. 1996, 75: 721-724.PubMed
101.
Madoiwa S, Nakamura Y, Mimuro J, Furusawa S, Koyama T, Sugo T, Matsuda M, Sakata Y: Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion. Blood. 2001, 97: 3783-3789. 10.1182/blood.V97.12.3783.PubMed
102.
Pasquier E, Amiral J, Martin LS, Mottier D: A cross-sectional study of anti-phospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost. 2001, 86: 538-542.PubMed
103.
Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T: Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996, 75: 456-459.PubMed
104.
Exner T, Kraus M: A monoclonal antibody against prothrombin fragment 1 behaves like a lupus anticoagulant (Letter). Thromb Haemost. 1999, 81: 470-471.PubMed
105.
Galli M, Beretta G, Daldossi M, Bevers RM, Barbui T: Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997, 77: 486-491.PubMed
106.
Atsumi T, Ieko M, Betolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, Koike T: Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000, 43: 1982-1993. 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2.PubMed
107.
Donohoe S, Mackie IJ, Isenberg D, Machin SJ: Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol. 2001, 113: 544-549. 10.1046/j.1365-2141.2001.02716.x.PubMed
108.
Guerin V, Smith O, White B, Sweetman G, Feighery C, Jackson J: Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders. Br J Haematol. 1998, 102: 896-902. 10.1046/j.1365-2141.1998.00876.x.PubMed
109.
Raynal P, Pollard HB: Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta. 1994, 1197: 63-93.PubMed
110.
Liemann S, Benz J, Burger A, Voges D, Hofmann A, Huber R, Gottig P: Structural and functional characterization of the voltage sensor in the ion channel human annexin V. Journal of Molecular Biology. 1996, 258: 555-61. 10.1006/jmbi.1996.0268.PubMed
111.
Nakamura N, Kuragaki C, Shidara Y, Yamaji K, Wada Y: Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am J Hematol. 1995, 49: 347-8. 10.1002/ajh.2830490414.PubMed
112.
Willems GM, Janssen MP, Confurius P, Galli M, Zwaal RF, Bevers EM: Competition of annexin V and anticardiolipin antibodies for binding to phosphatidyl serine containing membranes. Biochemistry. 2000, 38: 1982-1989. 10.1021/bi9921081.
113.
Simak J, Holada K, Vostal JG: Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin [on-line]. BMC Cell Biol. 2002, 3: 11-10.1186/1471-2121-3-11.PubMedCentralPubMed
114.
Pasquet J-M, Toti F, Nurden AT, Dachery-Prigent J: Procoagulant activity and active calpain in platelet-derived microparticles. Thromb Res. 1996, 82: 509-522. 10.1016/0049-3848(96)00101-6.PubMed
115.
Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernst JD, Lubin BH: Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood. 1996, 87: 1179-1187.PubMed
116.
Dachary-Prigent JD, Freyssinet J-M, Pasquet J-M, Carron J-C, Nurden AT: Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometric study showing a role for free sulfhydryl groups. Blood. 1993, 81: 2554-2565.PubMed
117.
Boersma AW, Nooter K, Oostrum RG, Stoter G: Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin. Cytometry. 1996, 24: 123-30. 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO;2-K.PubMed
118.
Savill J, Gregory C, Haslett C: Eat me or die. Science. 2003, 302: 516-517. 10.1126/science.1092533.
119.
Rauch J, Janoff AS: Antibodies against phospholipids other than cardiolipin: potential roles for both phospholipid and protein. Lupus. 1996, 5: 498-502.PubMed
120.
Donohoe S, Kingdom JCP, Mackie IJ, Burrell S, Quenby S, Jauniaux E, Machin SJ: Ontogony of β2 glycoprotein 1 and annexin V in villous placenta of normal and antiphospholipid syndrome pregnancies. Thromb Haemost. 2000, 84: 32-38.PubMed
121.
Rand JH, Wu XX, Andree HAM, Lockwood CJ, Guller S, Scher J, Harpel PC: Pregnancy loss in the antiphospholipid antibody syndrome – a possible thrombogenic mechanism. N Engl J Med. 1997, 337: 154-160. 10.1056/NEJM199707173370303.PubMed
122.
Galli M, Borrelli G, Jacobson EM, Marfisi RM, Finazzi G, Marchioli R, Wisloff F, Marziali S, Morboeuf O, Barbui T: Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. 2007, 110: 1178-1183. 10.1182/blood-2007-01-066043.PubMed
123.
Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M: Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody [see comments]. Am J Hematol. 1994, 47: 56-8. 10.1002/ajh.2830470112.PubMed
124.
Kuragaki C, Kidoguchi K, Nakamura N, Wada Y: Anti-annexin V antibodies in plasma and serum samples from patients with lupus anticoagulant [Letter on Matsuda et al]. American Journal of Hematology. 1995, 50: 68-10.1002/ajh.2830500122.PubMed
125.
Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y: Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol. 1997, 54: 209-13. 10.1002/(SICI)1096-8652(199703)54:3<209::AID-AJH6>3.0.CO;2-#.PubMed
126.
Dubois T, Bisagni-Faure A, Coste J, Mavoungou E, Menkes CJ, Russo-Marie F, Rothhut B: High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. J Rheumatol. 1995, 22: 1230-4.PubMed
127.
Rodriguez-Garcia MI, Fernandez JA, Rodriguez A, Fernandez MP, Gutierrez C, Torre-Alonso JC: Annexin V autoantibodies in rheumatoid arthritis. Ann Rheum Dis. 1996, 55: 895-900. 10.1136/ard.55.12.895.PubMedCentralPubMed
128.
Bohm BB, Wilbrink B, Kuettner KE, Mollenhauer J: Structural and functional comparison of anchorin CII (cartilage annexin V) and muscle annexin V. Archives of Biochemistry & Biophysics. 1994, 314: 64-74. 10.1006/abbi.1994.1412.
129.
Mukhopadhyay S, Cho W: Interactions of annexin V with phospholipid monolayers. Biochimica et Biophysica Acta. 1996, 1279: 58-62. 10.1016/0005-2736(95)00201-4.PubMed
130.
Zhang J, McCrae R: Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta-2-glycoprotein I antibodies [with editorial p1845]. Blood. 2005, 105: 1964-1969. 10.1182/blood-2004-05-1708.PubMed
131.
Kertesz Z, Yu BB, Steinkasserer A, Haupt H, Benham A, Sim RB: Characterization of binding of human β2-glycoprotein 1 to cardiolipin. Biochem J. 1995, 310: 315-321.PubMedCentralPubMed
132.
Arnout J, Wittevrongel C, Vermylen J: Phospholipid binding proteins and the antiphospholipid syndrome: A role for complement factor H?. Thromb Haemost. 1997, June (Suppl): Ab SC-1.
133.
Rampazzo P, Biasiolo A, Garin J, Rosato A, Betterle C, Ruffatti A, Pengo V: Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost. 2001, 85: 57-62.PubMed
134.
Jozsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF: Anti-factor H autoanibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood. 2007, 110: 1516-1518. 10.1182/blood-2007-02-071472.PubMed
135.
Bidot CJ, Jy W, Horstman LL, Huang H, Jimenez JJ, Yaniz M, Ahn YS: Factor VII/VIIa: A new antigen in the antiphospholipid antibody syndrome. Br J Haematol. 2003, 120: 618-626. 10.1046/j.1365-2141.2003.04161.x.PubMed
136.
Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS, Alexander JS, Gonzalez-Toledo E, Kelley RE, Minagar A: Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis. BMC Neurol. 2007, 7: 36-42. 10.1186/1471-2377-7-36.PubMedCentralPubMed
137.
Kolev K, Lerant I, Skopal J, Keleman A, Nagy Z, Machovich R: Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with antithrombin antibody from a patient with antiphospholipid syndrome. Thromb Haemost. 2005, 94: 82-87.PubMed
138.
Shinobu S, Harpel PC, Gharavi A, Rand J, Fillit H: Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin formation. Blood. 1994, 83: 2532-2540.
139.
Arnout J: The pathogenesis of the anti-phospholipid syndrome: A hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost. 1996, 75: 536-541.PubMed
140.
Cesarman-Maus G, Rios-Luna NP, Deora AB, Huang B, Villa R, Craviota MC, Alarcon-Segovia D, Sanchez-Guerrero J, Hajjar KA: Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome [with editorial by K.R. McCrae p4375-6]. Blood. 2006, 107: 4375-4382. 10.1182/blood-2005-07-2636.PubMedCentralPubMed
141.
Miesbach W, Matthias T, Scharrer I: Identification of thrombin antibodies in patients with antiphospholipid syndrome. Ann N Y Acad Sci. 2005, 1050: 250-256. 10.1196/annals.1313.026.PubMed
142.
Matsuda J, Matsuyama A, Atsumi G, Ohkura N: Sole existence of antithrombin antibody in patients with systemic lupus erythematosus showing tendency of its antigenic determinants directing against exosite II (antithrombin/heparin binding site) of thrombin. Blood Coagul Fibrinolysis. 2008, 19 (1): 66-69.PubMed
143.
Sugi T, McIntyre JA: Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood. 1995, 86: 3083-3089.PubMed
144.
Sanmarco M, Alessi MC, Harle JR, Sapin C, Aillaud MF, Gentile S, Juhan-Vague I, Weiller PJ: Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thrombosis. Thromb Haemost. 2001, 85: 800-805.PubMed
145.
Bertolaccini ML, Roch B, Armengual O, Atsumi T, Kamashta MA, Hughes GR: Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol. 1998, 37: 1229-1232. 10.1093/rheumatology/37.11.1229.PubMed
146.
Drouvalakis KA, Buchanan RR: Phospholipid specificity of autoimmune and drug induced lupus anticoagulants: association of phosphatidylethanolamine reactivated thrombosis in autoimmune disease. J Rheumatol. 1998, 25: 290-295.PubMed
147.
Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK: Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997, 17: 3159-3163.PubMed
148.
Steinerova A, Stozicky F, Racek J, Tatzber F, Zima T, Stetina R: Autoantibodies against oxidized LDL in infants. Clin Chem. 2001, 47: 1137-1138.PubMed
149.
Yang CD, Hwang KK, Yan W, Gallagher K, FitzGerald J, Grossman JM, Hahn BH, Chen PP: Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol. 2004, 172: 5765-5773.PubMed
150.
Cugno M, Cabibbe M, Galli M, Meroni PL, Caccia S, Russo R, Bottasso B, Mannucci PM: Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood. 2004, 103: 2121-2126. 10.1182/blood-2003-07-2422.PubMed
151.
Forastiero RR, Maetinuzzo ME, Broze GJ: High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost. 2003, 1: 718-724. 10.1046/j.1538-7836.2003.00102.x.PubMed
152.
Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T: Antibodies to β2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost. 2000, 84: 653-656.PubMed
153.
Barquinero J, Ordi-Ros J, Selva A, Perez-Peman P, Vilardell M, Kamashta M: Antibodies against platelet activating factor in patients with antiphospholipid antibodies. Lupus. 1993, 3: 55-58. 10.1177/096120339400300111.
154.
Vlachoyiannopoulos PG, Mavragani CP, Bourazopoulou E, Balitsari AV, Routsias JG: Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus. Thromb Haemost. 2004, 92: 1303-1311.PubMed
155.
DeGroot PG, Oosting JD, Derksen RHWM: Antiphospholipid antibodies: specificity and pathophysiology. Bailliere's Clin Hematol. 1993, 6: 691-709. 10.1016/S0950-3536(05)80194-5.
156.
Schorer AE, Duane PG, Woods VL, Niewoehner DE: Some antiphospholipid antibodies inhibit phospholipase A2 activity [with editorial pg 10-13]. J Lab Clin Med. 1992, 120: 67-77.PubMed
157.
Rock G, Chauhan K, Jamieson GA, Tandon NN: Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol. 1994, 88: 878-880. 10.1111/j.1365-2141.1994.tb05131.x.PubMed
158.
Pelegri Y, Cerrato G, Martinuzzo ME, Careras LO, Forastiero RR: Link between anti-CD36 antibodies and thrombosis in the antiphospholipid syndrome. Clin Exp Rheumatol. 2003, 21: 221-224.PubMed
159.
Rieger M, Mannucci PM, Hovinga JAK, Herzog A, Gerstenbauer G, Konetschny C, Zimmerman K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Pleimauer B, Lammle B, Scheiflinger F: ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005, 106: 1262-1267. 10.1182/blood-2004-11-4490.PubMed
160.
Gallimore MJ, Jones DW, Winter M: Factor XII determinations in the presence and absence of phospholipid antibodies. Thromb Haemost. 1998, 79: 87-90.PubMed
161.
Jones DW, Mackie IJ, Gallimore MJ, Winter M: Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol. 2001, 113: 550-552. 10.1046/j.1365-2141.2001.02776.x.PubMed
162.
Nuss R, Jacobson L, Hathaway WE, Manco-Johnson M, Study Group: Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors (letter). Thromb Haemost. 1999, 82: 1559-1560.PubMed
163.
Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, Hughes GRV: Immune mediated mechanism for thrombosis antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis. 1988, 47: 849-852. 10.1136/ard.47.10.849.PubMedCentralPubMed
164.
Out HJ, deGroot PG, vanVliet M, deGast GC, Nieuwenhuis HK, Derksen RH: Antibodies to platelets in patients with anti-phospholipid antibodies. Blood. 1991, 77: 2655-2659.PubMed
165.
Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S: Antiphospholipid antibodies enhance thrombin induced platelet activation and thromboxane formation. Thromb Haemost. 1993, 70: 667-671.PubMed
166.
Nozima J, Suehisa E, Kuratsune H, Machi T, Koike T, Kitani T, Kanakura Y, Amino N: Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus: Possible association with thrombotic and thrombocytopenic complications. Thromb Haemost. 1999, 81: 436-431.
167.
Tokita S, Arai M, Yamamoto N, Katagiri Y, Tanoue K, Igarashi K, Umeda M, Inoue K: Specific cross reaction of IgG anti-phospholipid antibody with platelet glycoprotein IIIa. Thromb Haemost. 1996, 75: 168-174.PubMed
168.
Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G: Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am. 2001, 27 (s): 587-602. 10.1016/S0889-857X(05)70222-2.PubMed
169.
Pierangeli SS, Espinola RG, Ferrara DE, Harris EN: Activation of endothelial cell nuclear factor kB by antiphospholipid antibodies. Blood. 2001, 98: 56b(A#3837).
170.
Simantov R, LaSala J, Lo S, Gharavi A, Sammaritano L, Salmon J: Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995, 96: 2211-2219. 10.1172/JCI118276.PubMedCentralPubMed
171.
Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL: Antiphospholipid antibodies activate vascular endothelial cells. Lupus. 1996, 5: 440-441.PubMed
172.
McCrae KR, DeMichele A, Samuels P, Roth D, Kuo A, Meng Q, Rauch J, Cines DB: Detection of endothelial cell-reactive immunoglobulin in patients with antiphospholipid antibodies. Br J Haematol. 1991, 79: 595-605. 10.1111/j.1365-2141.1991.tb08087.x.PubMed
173.
Oosting J, Derksen RH, Blokzijl L, Sixma L, deGroot PG: Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity – studies in a thrombosis model. Thromb Haemost. 1992, 68: 278-284.PubMed
174.
Carvalho D, Savage CO, Isenberg D, Pearson JD: IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. Arthritis Rheum. 1999, 42: 631-640. 10.1002/1529-0131(199904)42:4<631::AID-ANR5>3.0.CO;2-X.PubMed
175.
Papa ND, Rascho E, Moroni G, Panzeri P, Borghi MO, Ponticelli C, Tincani A, Balestrieri G, Meroni PL: Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a proadhesive and proinflammatory phenotype in vivo. Lupus. 1999, 8: 423-429. 10.1177/096120339900800603.PubMed
176.
Williams FMK, Parmar K, Hughes GRV, Hunt BJ: Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost. 2000, 84: 742-746.PubMed
177.
Porta C, Buggia I, Bonomi I, Caporali R, Scatola C, Montecucco C: Nitrite and nitrate plasma levels, as markers of nitric oxide synthesis, in antiphospholipid antibodies-related conditions and in thrombotic thrombocytopenic purpura (letter). Thromb Haemost. 1997, 78: 965-967.PubMed
178.
Martinuzzo ME, Forastiero RR, Carreras LO: Increased plasma thrombomodulin in different subgroups of patients with antiphospholipid and anti β2 glycoprotein 1 antibodies. Thromb Haemost. 1996, 75: 972-973.PubMed
179.
DelPapa N, Meroni PL, Tincani A, Harris EN, Pierangeli SS, Barcellini W, Borghi MO, Balestreira G, Zanussi C: Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol. 1992, 10: 37-42.
180.
Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS: E-selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2003, 1: 843-848. 10.1046/j.1538-7836.2003.00119.x.PubMed
181.
Branch DW, Rodgers GM: Induction of endothelial tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol. 1993, 168: 206-210.PubMed
182.
Atsumi T, Khamashta MA, Amengual O, Hughes GRV: Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost. 1997, 77: 222-223.PubMed
183.
Jy W, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J, Ahn YS: Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res. 2007, 121: 319-325. 10.1016/j.thromres.2007.04.014.PubMed
184.
Dueymes M, Levy Y, Ziporen L, Jamin C, Piette JC, Shoenfeld Y, Youinou P: Do some antiphospholipid antibodies target endothelial cells?. Ann Med Interne. 1996, 147 (Suppl 1): 22-23.
185.
Belizna C, Tervaert JW: Specificity, pathogenicity, and clinical value of antiendothelial cell antibodies. Semin Arthritis Rheum. 1997, 27: 98-109. 10.1016/S0049-0172(97)80010-8.PubMed
186.
Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou PY: The binding of some human anti-endothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998, 101: 2029-2035. 10.1172/JCI2261.PubMedCentralPubMed
187.
Edelsten C, D'Cruz D, Hughes GR, Graham EM: Anti-endothelial cel antibodies in retinal vasculitis. Curr Eye Res. 1992, 11 (Suppl): 203-208. 10.3109/02713689208999534.PubMed
188.
Ronda N, Leornado S, Orlandini G, Gatti R, Bellosta S, Bernini F, Borghetti A: Natural anti-endothelial cell antibodies (AECA). J Autoimm. 1999, 13: 121-127. 10.1016/S0896-8411(99)99999-7.
189.
Hill MB, Phipps JL, Hughes P, Greaves M: Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: Patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes. Br J Haematol. 1998, 103: 416-421. 10.1046/j.1365-2141.1998.00979.x.PubMed
190.
Navarro M, Cervera R, Teixido M, Reverter JC, Font J, Lopez-Soto A, Monteagudo J, Escolar G, Ingelmo M: Antibodies to endothelial cells and to β2-glycoprotein I in the anti phospholipid syndrome: prevalence and isotype distribution. Br J Rheumatol. 1996, 35: 523-528. 10.1093/rheumatology/35.6.523.PubMed
191.
deRochemonteix BG, Kobayashi T, Rosnoblet T, Lindsay M, Parton RG, Reber G, deMaistre E, Wahl D, Kruithof EKO, Gruenberg J, deMoerloose P: Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells. Arterioscler Thromb Vasc Biol. 2000, 20: 563-574.
192.
Matsuda J, Gotoh M, Gohchi K, Kawasugi K, Tsukamoto M, Saitoh N: Anti-endothelial cell antibodies to the endothelial hybridoma cell line (Eahy926) in systemic lupus erythematosus patients with antiphospholipid antibodies. Br J Haematol. 1997, 97: 227-232. 10.1046/j.1365-2141.1997.d01-2147.x.PubMed
193.
Nakamura N, Shidara Y, Kawaguchi N, Azuma C, Mitsuda N, Onishi S, Yamaji K, Wada Y: Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Com. 1994, 205: 1488-1493. 10.1006/bbrc.1994.2833.PubMed
194.
Shan H, Goldman J, Cunto G, Manuppello J, Chaiken I, Cines DB, Silberstein LE: Heterogeneity of anti-phospholipid and anti-endothelial cell antibodies. J Autoimm. 1998, 11: 651-660. 10.1006/jaut.1998.0242.
195.
Shoenfeld Y: Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome unraveled. Trends Immunol. 2003, 24: 2-4. 10.1016/S1471-4906(02)00007-8.PubMed
196.
Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni P, Tedesco F: Thrombus formation induced by antibodies to beta-2-glycoprotein-1 is complement dependent and requires a priming factor. Blood. 2005, 106: 2340-2346. 10.1182/blood-2005-03-1319.PubMed
197.
Munakata Y, Saito T, Mutsada K, Seino J, Shibata S, Sasoki T: Detection of complement-fixing antiphospholipid antibodies in associated with thrombosis. Thromb Haemost. 2000, 83: 728-731.PubMed
198.
Davis WD, Brey RL: Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol. 1992, 10: 455-460.PubMed
199.
Brekke OH, Michaelsen TE, Sandlie I: The structural requirements for complement activation by IgG: does it hinge on the hinge?. Immunol Today. 1995, 16: 85-90. 10.1016/0167-5699(95)80094-8.PubMed
200.
Hinton RC: Neurological symptoms associated with antiphospholipid antibodies. Sem Thomb Haemost. 1994, 20: 46-54. 10.1055/s-2007-1001888.
201.
Oliver-Minarro D, Sanchez-Ramon S, Rodriguez-Mahou M, Alvarez S, Fernandez-Cruz E: Isolated type 5 antimitochondrial autoantibodies are associated with a history of thrombocytopenia and fetal loss. Fertil Steril. 2007, 87: e17-18.PubMed
202.
Pinckard RN, Olson MS, Kelley RE, DeHeer DH, Palmer JD, O'Rourke RA, Goldfein S: Antibody independent activation of human C1 after interaction with heart subcellular membranes. J Immunol. 1973, 110: 1376-1382.PubMed
203.
Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA: Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest. 1975, 56: 740-750. 10.1172/JCI108145.PubMedCentralPubMed
204.
Kagiyama A, Savage HE, Michael LH, Hanson G, Entman ML, Rossen RD: Molecular basis of complement activation in ischemic myocardium: Identification of the specific molecules of mitochondrial origin that bind human C1q and fix complement. Circ Res. 1989, 64: 607-615.PubMed
205.
Baker WF, Bick RL: Antiphospholipid antibodies in coronary artery disease. Sem Thomb Haemost. 1994, 20: 27-43. 10.1055/s-2007-1001887.
206.
Baleva M, Boyanovsky B, Nokolov K, Kolarov Z, Nikolova M: High levels of IgA anticardiolipin antibodies in patients with systemic lups erythematosus, Henoch-Schonlein purpura, Sneddon's syndrome and recurrent pregnancy loss (Letter). Thromb Haemost. 1999, 82: 1774-1775.PubMed
207.
Borzini P, Riva M, Nembri P, Rossi E, Pagliaro P, Vergani P, Greppi P, Tantardini P: CD36 autoantibodies and thrombotic diathesis, thrombocytopenia and repeated early fetal losses. Vox Sang. 1997, 73: 46-48. 10.1046/j.1423-0410.1997.7310046.x.PubMed
208.
La Rosa L, Meroni PL, Tincani A, Balestrieri G, Faden D, Lojacono A, Morassi L, Brocchi E, Del Papa N, Gharavi A, et al: Beta 2 glycoprotein I and placental anticoagulant protein I in placenta from patients with antiphospholipid syndrome. Journal of Rheumatology. 1994, 21: 1684-93.PubMed
209.
Mercier E, Quere I, Mares P, Gris JC: Primary recurrent miscarriages and anti-beta-2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test (Letter). Blood. 1998, 92: 2993-2994.PubMed
210.
Vora S, Shetty S, Ghosh K: Thrombophilic dimensions of recurrent fetal loss in Indian patients. Blood Coagul Fibrinolysis. 2008, 19: 581-584.PubMed
211.
Ornoy A, Yacobi S, Matalon ST, Blank M, Blumenfeld Z, Miller RK, Shoenfeld Y: The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus. 2003, 12: 573-578. 10.1191/0961203303lu405oa.PubMed
212.
Salmon JE: Antiphospholipid antibodies revisited: A disorder initiated by inflammation [Theodore E Woodward Award]. Trans Am Clin Climatol Assoc. 2007, 118: 99-114.PubMedCentralPubMed
213.
Zwaal RFA, Comfurius P, Bevers EM: Platelet procoagulant activity and microvesicle formation: Its putative role in hemostasis and thrombosis (Review). Biochim Biophys Acta. 1992, 1180: 1-8.PubMed
214.
Nomura S, Yanabu M, Fukuroi T, Kido H, Kawakatsu T, Yamaguchi K, Suzuki M, Kokawa T, Yasunaga K: Anti-phospholipid antibodies bind to platelet microparticles in idiopathic (autoimmune) thrombocytopenic purpura. Ann Hematol. 1992, 65: 46-49. 10.1007/BF01715126.PubMed
215.
Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999, 104: 93-102. 10.1172/JCI4985.PubMedCentralPubMed
216.
Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Moal V, Sanmarco M, Sampol J: Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004, 91: 667-673.PubMed
217.
Vallar L, Regnault V, Latger-Cannard V, Lecompte T: Beta 2-glycoprotein I binding to platelet microparticle membrane specifically reduces immunoreactivity of glycoproteins IIb/IIIa. Thromb Haemost. 2001, 85: 314-319.PubMed
218.
Horstman LL, Ahn YS: Platelet microparticles: A wide-angle perspective (Review). Crit Rev Oncol/Hematol. 1999, 30: 111-142. 10.1016/S1040-8428(98)00044-4.
219.
Horstman LL, Jy W, Jimenez JJ, Ahn YS: Endothelial microparticles as markers of endothelial dysfunction [Review]. Frontiers in Bioscience. 2004, 9: 1118-1135. 10.2741/1270.PubMed
220.
Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA: Identification of patients a low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006, 296 (397–402).
221.
Bidot L, Jy W, Bidot C, Fontana V, Horstman LL, Ahn Y-S: Microparticle-mediated thrombin generation assay: enhanced activity in patients with recurrent thrombosis. J Thromb Haemost. 2007, 6: 913-919. 10.1111/j.1538-7836.2008.02963.x.
222.
Cheng HM: Antibodies to anionic phospholipids in normal human, rabbit, and mouse sera. Thromb Res. 1992, 66: 461-462. 10.1016/0049-3848(92)90296-M.PubMed
223.
Santiago MB, Bueno C, Vianna V, Cossermelli W, Oliviera RM: Influence of serum inactivation on detection of anticardiolipin antibodies (ACA) by ELISA. Clin Exp Rheumatol. 1989, 7: 99-100.PubMed
224.
Hasselaar P, Triplett DA, LaRue A, Derksen RHWM, Bookzijl L, deGroot PG, Wagenknecht DR, McIntyre JA: Heat treatment of serum and plasma induces false positive results in the antiphospholipid ELISA. J Rheumatol. 1990, 17: 186-191.PubMed
225.
Matsuda J, Tsukamoto M, Saitoh N, Gochi K, Kinoshita K: Absence of anticardiolipin antibody in non-treated and heat-inactivated normal human sera. Thromb Res. 1992, 68: 441-442. 10.1016/0049-3848(92)90104-I.PubMed
226.
McIntyre JA, Wagenknecht DR, Triplett DA: Detection of antiphospholipid antibodies in heat inactivated and normal human sera. Thromb Res. 1993, 69: 489-490. 10.1016/0049-3848(93)90237-I.PubMed
227.
Cabiedes J, Cabral AR, Alarcon-Segovia D: Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatment. Eur J Immunol. 1998, 28: 2108-2114. 10.1002/(SICI)1521-4141(199807)28:07<2108::AID-IMMU2108>3.0.CO;2-R.PubMed
228.
Kra-Oz Z, Lorber M, Shoenfeld Y, Scharff Y: Inhibitor(s) of natural anti-cardiolipin antibodies. Clin Exp Immunol. 1993, 93: 265-268.PubMedCentralPubMed
229.
Nguyen DH, Tangvoranuntakul P, Varki A: Effects of natural human antibodies against nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol. 2005, 175: 228-236.PubMed
230.
Cabiedes J, Cabral AR, Lopez-Mendoza AT, Cordero-Esperon HA, Huerta MT, Alarcon-Segovia D: Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects. J Autoimm. 2002, 18: 181-190. 10.1006/jaut.2001.0575.
231.
Sherer Y, Shoenfeld Y: The idiotypic network in antinuclear-antibody-associated diseases. Int Arch Allergy Immunol. 2000, 123: 10-15. 10.1159/000024419.PubMed
232.
Adib M, Ragimbeau J, Avrameas S, Ternynck T: IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol. 1990, 145: 3807-3813.PubMed
233.
Hurez V, Kazatchkine MD, Vassilev T, Ramanathan S, Pashov A, Basuyaux B, deKozak Y, Bellon B, Kaveri SV: Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood. 1997, 90: 4004-4013.PubMed
234.
Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, Zinkernagel RM: Control of early viral and bacterial distribution and disease by natural antibodies. Science. 1999, 286: 2156-2159. 10.1126/science.286.5447.2156.PubMed
235.
Stahl D, Lacroix-Desmazes S, Heudes , Mouthon L, Kaveri SV, Kazatchkine MD: Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia. Blood. 2000, 95: 328-335.PubMed
236.
Moreau A, Lacroix-Desmazes S, Stieltjes N, Saenko E, Kaveri SV, DíOiron R, Sultan Y, Scandella D, Kazatchkine MD: Antibodies to the FVIII light chain that neutralizes FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood. 2000, 95: 3345-3441.
237.
Pan ZJ, Anderson CJ, Stafford HA: Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J Clin Invest. 1998, 102: 215-222. 10.1172/JCI1969.PubMedCentralPubMed
238.
Quan CP, Quan CP, Watanabe S, Pamonsinlapatham P, Bouvet JP: Different dysregulations of the natural antibody repertoire in treated and untreated HIV-1 patients. J Autoimm. 2001, 17: 81-87. 10.1006/jaut.2001.0529.
239.
Shoenfeld Y: Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J. 1994, 8: 1296-1301.PubMed
240.
Fischer P, Jendreyko N, Hoffmann M, Lerch H, Uttenreuther-Fischer MM, Chen PP: Platelet-reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia. Br J Haematol. 1999, 105: 626-640. 10.1046/j.1365-2141.1999.01407.x.PubMed
241.
Yang YY, Fischer P, Leu SI, Zhu M, Woods VL, Chen PP: Possible presence of enhancing antibodies in idiopathic thrombocytopenic purpura. Br J Haematol. 1999, 104: 69-80. 10.1046/j.1365-2141.1999.01144.x.PubMed
242.
Yasuda S, Bohgaki M, Atsumi T, Koika T: Pathogenesis of antiphospholipid antibodies: importance of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiol. 2005, 210: 775-780. 10.1016/j.imbio.2005.10.009.
243.
Pierangeli SS, Chen PP, Reschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL: Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms [with other relevant articles in this special issue and prior one]. Sem Thromb Hemost. 2008, 34: 236-250. 10.1055/s-0028-1082267.
244.
Galli M, Luciani D, Bertolini G, Barbui T: Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003, 101: 1827-1832. 10.1182/blood-2002-02-0441.PubMed
245.
Matsuura E, Igarashi Y, Yasuda T, Koike T, Triplett DA, Koike T: Anticardiolipin antibodies recognize β2-glycoprotein 1 structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994, 179: 457-462. 10.1084/jem.179.2.457.PubMed
246.
Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD: The orientation of β2GP1 on the plate is important for the binding of anti-β2GP1 autoantibodies by ELISA. J Autoimm. 2002, 18: 289-297. 10.1006/jaut.2002.0590.
247.
Nomura S, Yanabu M, Miyake T, Miyazaki Y, Kido H, Kagawa H, Fukuhara S, Komiyama Y, Matsuura E, Koike T: Relationship of microparticles with beta2-glycoprotein I and P-selectin positivity to anticardiolipin antibodies in immune thrombocytopenic purpura. Ann Hematol. 1995, 70: 25-30. 10.1007/BF01715378.PubMed
248.
Hoefner DM, Yeo KTJ: Lot-to-lot inconsistency of anticardiolipin reagents. Clin Chem. 2002, 48: 1625-1626.PubMed
249.
Merkel PA, Chang Y, Pierangeli SS, Harris EN, Polisson RP: Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue disease. J Rheumatol. 1999, 26: 591-596.PubMed
250.
Kilpatrick DC: Factors affecting cardiolipin antibody assays: modification with polyethylene glycol compound. Br J Haematol. 1998, 100: 52-57. 10.1046/j.1365-2141.1998.00532.x.PubMed
251.
Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, deMoerloose P, Boffa MC, Arvieux J: Inter-laboratory variability of anti-β2-glycoprotein I measurement: Collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost. 2002, 88: 66-73.PubMed
252.
Ming CH, Fan YS: Enhancement of anti-phospholipid antibody activity by Tween 20. J Immunol Meth. 1988, 109: 253-255. 10.1016/0022-1759(88)90250-5.
253.
Cabral AR, Cabiedes J, Alarcon-Segovia D: Tween 20 detaches cardiolipin from ELISA plates and makes anticardiolipin antibodies undetectable regardless of the presence of β2-glycoprotein 1. J Immunol Meth. 1994, 175: 107-114. 10.1016/0022-1759(94)90336-0.
254.
Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M: Distinguishing β2-glycoprotein 1 dependent (systemic lupus erythematosus type) and independent (syphilis type) anticardiolipin antibody with Tween 20. Br J Haematol. 1993, 85: 799-802. 10.1111/j.1365-2141.1993.tb03226.x.PubMed
255.
Nava A, Banales JL, Reyes PA: Heat inactivation of bovine serum used for blockade in immunoenzymatic assay is associated with spurious fall on the titers of anticardiolipin antibodies in primary antiphospholipid syndrome sera. J Clin Lab Anal. 1993, 7: 116-118. 10.1002/jcla.1860070209.PubMed
256.
Lockshin MD, Qamar Q, Levy RA, Best MP: IgG but not IgM anti-phospholipid antibody binding is temperature dependent. J Clin Immunol. 1988, 8: 188-192. 10.1007/BF00917565.PubMed
257.
Kamikubo Y, Miyamoto S, Iwasa A, Ishii M, Okajima K: Purification and characterization of factor VII inhibitor found in a patient with life-threatening bleeding. Thromb Haemost. 2000, 83: 60-64.PubMed
258.
Wong RCW, Favaloro EJ: The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-b2-glycoprotein-1 ELISAs: a rebuttal [Response to Lewis et al, JTH 4:265]. J Thromb Haemost. 2006, 4: 1-2. 10.1111/j.1538-7836.2005.01773.x.
259.
Ahn ER, Lander G, Jy W, Bidot C, Jimenez JJ, Horstman LL, Ahn YS: Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk. Thromb Res. 2004, 114: 143-148. 10.1016/j.thromres.2004.06.005.PubMed
260.
Selva-O'Callaghan A, Ordi-Ros J: IgA anticardiolipin antibodies – relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost. 1998, 79: 282-285.PubMed
261.
Gargulio P, Goldberg J, Romani B, Schiaffini R, Ciampalini P, Faulk WP, McIntyre JA: Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus. Clin Exp Immunol. 1999, 118: 30-34. 10.1046/j.1365-2249.1999.01014.x.
262.
Wahl DG, Guillemin F, deMaistre E, Perret-Guillaume C, Lecompte T, Thibaut G: Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998, 7: 15-22. 10.1191/096120398678919688.PubMed
263.
Wahl DG, Guillemin F, deMaistre E, Perret C, Lecompte T, Thibaut G: Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus, a meta-analysis. Lupus. 1997, 6: 467-473. 10.1177/096120339700600510.PubMed
264.
Harris EN, Pierangeli S, Birch D: Anticardiolipin wet workshop report. Fifth international symposium on antiphospholipid antibodies. Am J Clin Pathol. 1994, 101: 616-624.PubMed
265.
Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC: Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations. A Cooperative Project of the European Antiphospholipid Forum. Thromb Haemost. 2001, 86: 575-583.PubMed
266.
Pierangeli SS, Harris EN: A quarter of a century of in anticardiolipin testing and attempted standardization has led us to here, which is?. Semin Thromb Hemost. 2008, 34: 313-328. 10.1055/s-0028-1085473.PubMed
267.
Fontaine M, Hamburger HA, Nichols WL: Persistent problems with standardization of immunoassays for anti-cardiolipin antibodies (Letter). Thromb Haemost. 2001, 86: 1123-1124.PubMed
268.
Margolius A, Jacksom DP, Ratnoff OD: Circulating anticoagulants: A study of 40 cases and a review of the literature. Medicine. 1961, 40: 145-202. 10.1097/00005792-196105000-00002.PubMed
269.
Aggeler PM, Lindsay S, Lucia SP: Studies on the coagulation defect in a case of thrombocytopenic purpura complicated by thrombosis. Am J Pathol. 1946, 22: 1181.PubMedCentralPubMed
270.
Conley CL, Rathbun HK, Morse WI, Robinson JE: Circulating anticoagulants as a cause of hemorrhagic diathesis in man. Bull Johns Hopkins Hosp. 1948, 83: 288-293.PubMed
271.
Bowie EJW, Thompson JH, Jacuzzi CA, Owen CA: Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963, 62: 416-430.PubMed
272.
Gharavi W, Harris EN, Asherson RA, Hughes GRV: Anti-cardiolipin antibodies: Isotope distribution and phospholipid specificity. Ann Rheum Dis. 1987, 46: 1-6. 10.1136/ard.46.1.1.PubMedCentralPubMed
273.
Mueh JR, Herbst KD, Rapaport SI: Thrombosis in patients with the lupus anticoagulant. Ann Int Med. 1980, 92: 156-159.PubMed
274.
Derkens RHWM, Hasselaar P, Blokzijl L, Frits HJ, Myling G, DeGroot PG: Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of patients. Ann Rheum Dis. 1988, 47: 364-371. 10.1136/ard.47.5.364.
275.
Ferro D, Quintarelli C, Valasini G, Violi F: Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus. Blood. 1993, 82.
276.
Ghiradello A, Doria A, Ruffatti A, Rigoli AM, Vesco P, Calligaro A, Bambari PF: Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?. Ann Rheum Dis. 1994, 53: 140-142. 10.1136/ard.53.2.140.
277.
Ames PR, Pyke S, Iannaccone L, Brancaccio V: Antiphospholipid antibodies, hemostatic variables and thrombosis – a survey of 144 patients. Thromb Haemost. 1995, 73: 768-773.PubMed
278.
Horbach DA, vanOort E, Donders RCJM, Derksen RHWM, deGroot PG: Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996, 76: 916-924.PubMed
279.
Roubey RAS, Pratt CW, Buyon JP, Winfield JB: Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein 1. J Clin Invest. 1992, 90: 1100-1104. 10.1172/JCI115926.PubMedCentralPubMed
280.
Arvieux J, Pouzol P, Roussel B, Jacob MC, Colomb MG: Lupus-like anticoagulant properties of murine antibodies to beta2-glycoprotein I. Br J Haematol. 1992, 81: 568-573. 10.1111/j.1365-2141.1992.tb02993.x.PubMed
281.
Arnout J, Wittevrongel C, Vermylen J: Murine monoclonal antibodies against beta-2-glycoprotein 1 have lupus anticoagulant activity. Thromb Haemost. 1997, June (Suppl): 154 (Ab PD-630).
282.
Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RF, Bevers EM: Kinetics of prothrombin-mediated binding of lupus anticoagulant antibodies to phosphatidyl serine-containing phospholipid membranes: an ellipsometric study. Biochemistry. 2002, 41: 14357-14363. 10.1021/bi026408l.PubMed
283.
Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, Ichikawa K, Koike T, Suzuki K: Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest. 1997, 99: 2260-2268. 10.1172/JCI119401.PubMedCentralPubMed
284.
Bevers EM, Galli M: Cofactors involved in the antiphospholipid syndrome. Lupus. 1992, 1: 51-53. 10.1177/096120339200100201.PubMed
285.
Permpikul P, Rao LV, Rapaport SI: Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994, 15 (83): 2878-2892.
286.
Semmelink MJA, Derksen RHWM, Arnout J, deGroot PG: A simple method to discriminate between beta2-glycoprotein I and prothrombin-dependent lupus anticoagulants. J Thromb Haemost. 2003, 1: 740-747. 10.1046/j.1538-7836.2003.00146.x.
287.
Field SL, Hogg PJ, Daly EB, Dai YP, Murray B, Owens D, Chesterman CN: Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood. 1999, 94: 3421-3431.PubMed
288.
Field SL, Chesterman CN, Hogg PJ: Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies (Letter). Thromb Haemost. 2000, 84: 1132-1133.PubMed
289.
Rand JH, Wu XX, Giesen P: A possible solution to the paradox of the "lupus anticoagulant": antiphospholipid antibodies accelerate thrombin generation by inhibiting annexin V (Letter). Thromb Haemost. 1999, 82: 1376-1377.PubMed
290.
Rand JH, Wu XX, Lapinski R, vanHeerde WL, Reutelingsberger CP, Chen PP, Ortel TL: Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasma of patients with the antiphospholipid antibody syndrome [Editorial pg 2619]. Blood. 2004, 104: 2783-2790. 10.1182/blood-2004-01-0203.PubMed
291.
deLaat B, Wu XX, vanLummel M, Derksen RHWM, deGroot PG, Rand JH: Correlation between antiphospholipid antibodies that recognize domain I o beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007, 109: 1490-1494. 10.1182/blood-2006-07-030148.
292.
Tripodi A, Mancuso ME, Chantarangkul V, Clerici M, Bader R, Meroni PL, Santagostino E, Mannucci PM: Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: Considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem. 2005, 51: 1883-1885. 10.1373/clinchem.2005.054312.PubMed
293.
Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, Yamazaki M, Suga Y, Takami A, Miyamoto K, Nakao S: Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coag Fibrinolysis. 2001, 12: 1-8. 10.1097/00001721-200101000-00001.
294.
Ijdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM, Greco TP: Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?. Lupus. 1999, 8: 109-115. 10.1191/096120399678847461.PubMed
295.
Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR: Can neurological manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000, 79: 57-68. 10.1097/00005792-200001000-00006.
296.
Karussis D, Leker RR, Ashkenazi A, Abramsky O: A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. Ann Neurol. 1998, 44: 629-634. 10.1002/ana.410440408.PubMed
297.
Hughes GRV: The antiphospholipid syndrome and 'multiple sclerosis' [with editorial, pg 109–115]. Lupus. 1999, 8: 89-10.1191/096120399678847579.PubMed
298.
Moore PM, Lahita RG: Neuropsychiatric manifestations of system lupus erythematosus. Proceedings of a conference. Ann NY Acad Sci. 1997, 823: 1-328. 10.1111/j.1749-6632.1997.tb48376.x.PubMed
299.
Brey RL, Escalante A: Neurological manifestations of antiphospholipid antibody syndrome. Lupus. 1998, 7 (suppl 2): S67-S74.PubMed
300.
Miesbach W: Neurological symotoms as a feature of antiphospholipid syndrome. Semin Thromb Hemost. 2008, 34: 286-289. 10.1055/s-0028-1082273.PubMed
301.
Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D: Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke. 1992, 23: 189-193.PubMed
302.
Han MH, Hwang SU, Roy DB, Lundgren DH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L: Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008, 451: 1076-1080. 10.1038/nature06559.PubMed
303.
Minagar A, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Ahn YS, Sheremata WA: Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2001, 56: 1319-1324.PubMed
304.
Horstman LL, Minagar A, Jy W, Bidot CJ, Jimenez JJ, Ahn YS: Cell-derived microparticles and exosomes in neuroinflammatory conditions [Review]. Int Rev Neurobiol. 2007, 79: 229-268.
305.
Shoenfeld Y, Sherer Y, Blank M: Systemic involvement in the antiphospholipid syndrome: Lessons from animal models. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Edited by: Asherson RA, Cervera R, Piette JC, Shoenfeld Y. 2002, New York: Elsevier, 101-106.
306.
Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Pick OBCG, Leider-Trajo L, Kalshnikova L, Blank M, Chapman J: Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus. 2003, 12: 435-442.
307.
Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD: Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest. 1997, 100: 613-619. 10.1172/JCI119572.PubMedCentralPubMed
308.
Tsukada N, Tanaka Y, Miyagi K, Yanagisawa N, Okana A: Autoantibodies to each protein fraction extracted from cerebral endothelial cell membrane in the sera of patients with multiple sclerosis. J Neuroimmunol. 1989, 24: 41-46. 10.1016/0165-5728(89)90096-9.PubMed
309.
Souberbielle BE, Swingler RJ, Davidson DLW, Cull RE, Atkinson S, Davison I, Anderson J, Bell JE, Russell WC: Western blotting analysis in patients with MS using human brain vessels as antigens. Acta Neurol Scand. 1992, 86: 397-402. 10.1111/j.1600-0404.1992.tb05107.x.PubMed
310.
Tintore M, Fernandez AL, Rovira A, Martinez X, Direskeneli H, Kamashta M, Schwartz S, Codina A, Montalban X: Antibodies against endothelial cells in patients with multiple sclerosis. Acta Neurol Scand. 1996, 93: 416-420.PubMed
311.
Trojano M, Defazio G, Ricchiuti F, DeSalvia R, Livrea P: Serum IgG to brain microvascular endothelial cells in multiple sclerosis. J Neurol Sci. 1996, 143: 107-113. 10.1016/S0022-510X(96)00184-0.PubMed
312.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis (Review). New Engl J Med. 2000, 343: 938-952. 10.1056/NEJM200009283431307.PubMed
313.
Ahn YS, Horstman LL, Jy W, Jimenez JJ, Bowen B: Vascular dementia in patients with immune thrombocytopenic purpura (ITP). Thromb Res. 2002, 107: 337-344. 10.1016/S0049-3848(02)00337-7.PubMed
314.
Bidot CJ, Jy W, Horstman LL, Jimenez JJ, Yaniz M, Lander G, Ahn YS: Antiphospholipid antibodies in idiopathic thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol. 2004, 128: 366-372. 10.1111/j.1365-2141.2004.05314.x.
315.
Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS: Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol. 2006, 81: 391-396. 10.1002/ajh.20571.PubMed
316.
Schultz DA, Arnold PI, Jy W, Valant P, Gruber J, Ahn YS, Mao FW, Horstman LL: Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kd form of CD36 as a target antigen. Br J Hematol. 1998, 103: 849-857. 10.1046/j.1365-2141.1998.01070.x.
317.
Bidot CJ, Jy W, Ortega C, Horstman LL, Bidot C, Petit C, Fontana V, Yaniz M, Ahn Y: Patients with recurrent vs. isolated thrombosis have increased prevalence of anti-CD36 (Gp IV) and elevated endothelial microparticles. Blood. 2007, 110.
318.
Prieto J, Yuste JR, Beloqui O, Cuiveira MP, Riezu JI, Aguirre B, Sangro B: Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatol. 1996, 23: 199-204. 10.1002/hep.510230201.
319.
Constans J, Guerin V, Couchouron A, Seigneur M, Ryman M, Blann AD, Amiral J, Amara A, Peuchant E, Moreau JF, Pellegrini I, Pellegrini JL, Fleury H, Leng B, Conri C: Autoantibodies directed against phospholipids or human beta 2-glycoprotein I in HIV-seropositive patients: relationship with endothelial activation and anti-malonic dialdehyde antibodies. Eur J Clin Invest. 1998, 28: 115-122. 10.1046/j.1365-2362.1998.00254.x.PubMed
320.
Zhang R, Lifson JD, Chougnet C: Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions [Editorial p1743]. Blood. 2006, 107: 1989-1995. 10.1182/blood-2005-07-2731.PubMedCentralPubMed
Metadata
Title
Antiphospholipid antibodies: Paradigm in transition
Authors
Lawrence L Horstman
Wenche Jy
Carlos J Bidot
Yeon S Ahn
Roger E Kelley
Robert Zivadinov
Amir H Maghzi
Masoud Etemadifar
Seyed Ali Mousavi
Alireza Minagar
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2009
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-6-3

Other articles of this Issue 1/2009

Journal of Neuroinflammation 1/2009 Go to the issue

Research

Modulation of experimental autoimmune encephalomyelitis by endogenous Annexin A1

Research

Beyond blood brain barrier breakdown – in vivodetection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI

Research

A MT1-MMP/NF-κB signaling axis as a checkpoint controller of COX-2 expression in CD133(+) U87 glioblastoma cells

Review

ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology

Research

Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination

Research

Ciliary neurotrophic factor (CNTF) plus soluble CNTF receptor α increases cyclooxygenase-2 expression, PGE2release and interferon-γ-induced CD40 in murine microglia